Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Veterinary Protocols for AAV Gene Therapy Administration in Piglet Models in Germany

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Veterinary Protocols for AAV Gene Therapy Administration in Piglet Models in Germany

Veterinary Protocols for AAV Gene Therapy Administration in Piglet Models

CELL & GENE | RNA | BIOLOGICS

Successful AAV gene therapy development depends on robust, translationally relevant studies in large animal models. The piglet model offers significant anatomical and physiological parallels to human pediatrics, making it an ideal system for evaluating in vivo safety and tolerance prior to clinical entry. This asset details the key veterinary and regulatory protocols for conducting AAV administration studies in piglet models within the United States, focusing on GxP-compliant procedures, rigorous animal welfare standards, and the proper execution of systemic and muscle-directed vector delivery.

    Why is the piglet model preferred for certain AAV gene therapy studies?

    A: The piglet’s cardiovascular, metabolic, and immune systems share high homology with human infants. This similarity is invaluable for refining in-life procedures, including administration techniques and clinical monitoring plans, to better anticipate challenges in first-in-human trials.

    What are the key animal welfare considerations in the US?

    A: All protocols must secure approval from an Institutional Animal Care and Use Committee (IACUC) and adhere to stringent USDA animal welfare regulations. A core component of this is the ethical application of the 3Rs: Replacement, Reduction, and Refinement, overseen by our AAALAC-accredited programs.

    What AAV serotypes are effective for systemic delivery in large animal models?

    A: Serotypes with broad tropism, such as AAV9, are frequently used for systemic administration protocols. As demonstrated in foundational research, even muscle-tropic vectors can be administered systemically, a strategy that informs the design of the in-life phase for certain therapeutic approaches.

    How are dosing procedures refined for large animal models?

    A: Dose volume and administration rate calculations begin with allometric scaling, which adjusts for body weight and metabolic differences between species. These calculations are then refined within the study protocol, which is executed under strict veterinary oversight to ensure animal safety and procedural consistency.

Strategic Protocol Design for Large Animal AAV Studies

Executing AAV gene therapy studies in piglet models requires a deep integration of veterinary expertise and regulatory knowledge. The primary objective of the in-life phase is to ensure procedural success and animal well-being, generating high-quality samples and observations. These in-life operations are a key component of programs that typically span an 18-24 month timeline to support an Investigational New Drug (IND) application.

Our approach focuses on meticulous planning and execution of the in-life phase within our US-based facilities. This includes defining age-appropriate handling procedures, establishing precise intravenous or intramuscular administration techniques under veterinary supervision, and implementing a rigorous schedule for clinical observation and biological sample collection.

)

A scientist in a lab coat and gloves loads samples into a ProteinSimple instrument for analysis.

A researcher in a lab coat and blue gloves gently holds three white lab mice, symbolizing animal models in scientific research.

Vector Administration and In-Life Monitoring

The choice of AAV vector directly informs the design of the administration protocol and subsequent in-life monitoring plan. Insights from publications such as PMID: 34454844 highlight the principle that systemic delivery of a muscle-tropic AAV vector can produce a widespread biological effect. This knowledge helps shape the in-life study design for specific inherited metabolic diseases, ensuring the administration route and monitoring strategy are aligned with the therapeutic goal.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

Our veterinary staff executes these complex protocols within our >100,000 sq ft GxP-compliant facility. All procedures, from vector administration to routine health checks and sample collection, are performed according to IACUC-approved plans designed to ensure the highest standards of care.

Animal Welfare and GxP Compliance

All in vivo operations are conducted in strict accordance with USDA regulations. Our programs are designed to meet the highest ethical standards, incorporating the 3Rs (Replacement, Reduction, and Refinement) as mandated by our AAALAC-accredited animal welfare programs. This includes environmental enrichment, social housing where appropriate, and the use of minimally invasive techniques for sample collection. These measures ensure the scientific integrity of the study and the well-being of the animals.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities